Nanohybrid polymers for ophthalmic applications

Information

  • Patent Grant
  • 7745555
  • Patent Number
    7,745,555
  • Date Filed
    Monday, November 19, 2007
    16 years ago
  • Date Issued
    Tuesday, June 29, 2010
    14 years ago
Abstract
The present invention relates to novel materials particularly useful for ophthalmic applications and methods for making and using the same. More particularly, the present invention relates to relatively soft, optically transparent, foldable, high refractive index materials particularly suited for use in the production of intraocular lenses, contact lenses, and other ocular implants and to methods for manufacturing and using the same.
Description
FIELD OF THE INVENTION

The present invention relates to novel materials particularly useful for ophthalmic applications and methods for making and using the same. More particularly, the present invention relates to relatively soft, optically transparent, foldable, high refractive index materials particularly suited for use in the production of intraocular lenses, contact lenses, and other ocular implants and to methods for manufacturing and using the same.


BACKGROUND OF THE INVENTION

Since the 1940's optical devices in the form of intraocular lenses (IOLs) have been utilized as replacements for diseased or damaged natural ocular lenses. In most cases, an intraocular lens is implanted within an eye at the time of surgically removing the diseased or damaged natural lens, such as for example, in the case of cataracts. For decades, the preferred material for fabricating such intraocular lenses was poly(methyl methacrylate), which is a rigid, glassy polymer.


Softer, more flexible IOLs have gained in popularity in recent years due to their ability to be compressed, folded, rolled or otherwise deformed. Such softer IOLs may be deformed prior to insertion thereof through an incision in the cornea of an eye. Following insertion of the IOL in an eye, the IOL returns to its original, pre-folded shape due to the memory characteristics of the soft material. Softer, more flexible IOLs as just described may be implanted into an eye through an incision that is less than 4.0 mm i.e., much smaller than the 5.5 to 8.0 mm necessary to implant more rigid IOLs. A larger incision is necessary for more rigid IOLs because the lens must be inserted through an incision in the cornea slightly larger than the diameter of the inflexible IOL optic portion. Accordingly, more rigid IOLs have become less popular in the market since larger incisions have occasionally been found to be associated with an increased incidence of postoperative complications, such as induced astigmatism.


With recent advances in small-incision cataract surgery, increased emphasis has been placed on developing soft, foldable polymer materials suitable for use in artificial IOLs. In general, these materials fall into one of three categories: hydrogels, silicones and low glass transition temperature acrylics.


In general, high water content hydrogel materials have relatively low refractive indexes, making them less desirable than other materials with respect to minimal incision size. Low refractive index materials require a thicker IOL optic portion to achieve a given refractive power. Silicone materials may have a higher refractive index than high-water content hydrogels, but tend to unfold too rapidly after being placed in the eye in a folded position. A too rapid unfolding of a folded lens can potentially damage the corneal endothelium and/or rupture the natural lens capsule and associated zonules. Low glass transition temperature acrylic materials are desirable because they typically have a high refractive index and unfold more slowly and more controllably than silicone materials when inserted into e.g., the lens capsule. Unfortunately, low glass transition temperature acrylic materials, which contain little or no water initially, may absorb pockets of water, in vivo, causing light reflections or “glistenings”. Furthermore, it is difficult to achieve ideal folding and unfolding characteristics due to the temperature sensitivity of the acrylic polymers.


U.S. Pat. No. 5,480,950 issued Jan. 2, 1996 teaches of high refractive index hydrogel materials having a hydrated equilibrium water content of at least 57% for use in the manufacture of IOLs. The high refractive index hydrogel materials are cross-linked polymers prepared from mixtures of N-vinylpyrrolidone, 4-vinylpyrimidine and a vinyl pyridine having equilibrium water contents up to 90% and refractive indexes of 1.560 to 1.594 in the dry state. The IOLs as described are not implanted in a hydrated state. Rather, the IOLs are implanted in a dry, folded and elongated state and hydrated in situ. The refractive indexes in the hydrated state as used in the eye are not provided.


U.S. Patent Application Publication 2002/0049290 relates to high refractive index (RI) ophthalmic hydrogel materials


U.S. Pat. No. 5,693,095 issued Dec. 2, 1997 teaches of high refractive index, low water content IOL materials. The materials taught in this particular patent are acrylic materials having an elongation of at least 150%. IOLs manufactured from a material having such elongation characteristics will not crack, tear or split when folded. However, such low water content acrylic materials have been found to be less biocompatible than other materials when manufactured into and used as IOL devices.


In the past decade, hydrophobic polymers have been used in IOL manufacturing with some success. The ophthalmic community has accepted this type of polymer as having good physical properties and acceptable biocompatibility in ocular environments. However, current IOLs made from conventional hydrophobic polymers sometimes suffer from poor optical stability in ocular fluids (e.g. glistenings, optical artifacts) and low refractive indices. The formation of unwanted particles and deposits in the bulk of hydrophobic polymers is attributed to uncontrolled water sorption and subsequent phase separation. Conventional homopolymers currently used to produce copolymers with high RIs (>1.51) absorb varying amounts of water in a sporadic fashion, creating phase separation, haze, and glistenings.


Currently, there are no foldable, high RI IOL polymers that resist the formation of glistenings and deposits.


SUMMARY OF THE INVENTION

The present invention is a new family of high RI polymers particularly suitable for, but not limited to, foldable IOL applications. Materials of this invention are optically stable in ocular fluids and resist the formation of unwanted optical artifacts. The unusual properties of the copolymers of this invention are achieved by creating nanoclusters of a generally hydrophilic polymer within a very hydrophobic polymer matrix. Water sorption is minimized and limited to the nanoclusters. In addition, the limited amount of water that is absorbed is well distributed and well dispersed within the matrix, preventing macrophase separation noted in prior art compositions. The approximate nanosize diameter of the clusters is in the range of 1.0 Mn or less. Generally speaking the sizes of clusters operable in this invention will be of a diameter small enough so as to have little or interaction between visible light and the polymer network. The result is an optically clear material with stable optical properties.


This invention relates to novel copolymers for intraocular lenses (“IOL”), contact lens, and other ophthalmic and optical applications. IOLs made from the materials of this invention have a very high refractive index, and may be machined at around room temperature. IOLs of this invention may be folded and used to replace a defective natural lens of the eye by insertion through a small incision without the need for further processing or hydration. A particular advantage of the materials of this invention is their unusual hybrid character that prevents uncontrolled water sorption.


Foldable ophthalmic lens materials having controllable, uniform, relatively high water content and unexpectedly high refractive indices particularly suited for use as intraocular lenses (IOLs), or other ophthalmic devices such as but not limited to contact lenses, keratoprostheses and corneal rings or inlays, are the primary loci of the present invention.


This invention relates to copolymer compositions comprising limited amounts of a monomer having, for example, a carbazole and/or naphthyl moiety, carbazole, naphthalene, or a naphthyl group and a hydrophobic monomer. Carbazole and or naphthyl moiety monomers are added to the comonomer to increase the refractive index of the comonomer and increase the ability of the copolymer material to block blue light (wavelength up to 475 nm). A monomer having a surface tension generally in the range of 50 dyn/cm or less is used to create a very hydrophobic matrix. A hydrophilic polymer is added to create nanoclusters (in a process described below) for controlled water sorption.


Accordingly, it is an object of the present invention to provide a biocompatible IOL material having a high refractive index.


Another object of the present invention is to provide an IOL material having a high refractive index and controlled water sorption;


Still another object of the present invention is to provide an IOL material that is relatively simple to manufacture.


These and other objectives and advantages of the present invention, some of which are specifically described and others that are not, will become apparent from the detailed description and claims that follow.







DETAILED DESCRIPTION OF THE INVENTION

Materials of the present invention with high refractive indexes are desirable to allow manufacturers to manufacture thinner IOLs. A thin IOL or thin IOL optic is critical in enabling a surgeon to minimize incision size. Keeping the surgical incision size to a minimum reduces intraoperative trauma and postoperative complications. A thin IOL is also critical for accommodating certain anatomical locations in the eye such as the anterior chamber and the ciliary sulcus. IOLs may be placed in the anterior chamber for increasing visual acuity in both aphakic and phakic eyes and placed in the ciliary sulcus for increasing visual acuity in phakic eyes.


The preferred materials of the present invention have the flexibility required to allow the same to be folded or deformed so that IOLs made therefrom may be introduced into an eye through the smallest possible incision.


The novel materials of the present invention are copolymers, trimers, tetramers, etc., comprising three primary monomeric components: a high refractive index (RI) monomer, a hydrophobic monomer, and a hydrophilic monomer. A cross linker generally is included as is a UV absorber.


A high refractive index (RI) monomer of the present invention comprises a fused ring aromatic moiety coupled to an ethylenically unsaturated or vinylically unsaturated moiety. By the term “high refractive index monomer” it is intended that a polymer of the high RI monomer (i.e., a homopolymer of the monomer) has a refractive index of at least 1.50, preferably at least 1.53, and most preferably at least 1.56.


A vinylic or ethylene unsaturated moiety is, of course, well known to the art generally to mean a structure of the sort,




embedded image


wherein:

    • R1-R4 are separately and independently, H, C, X, or Rc;
    • Rc is any hydrocarbon moiety; and
    • X is any heteratom, providing that at least one of R1-R4 must be a fused ring aromatic structure or moiety as is discussed below. The fused ring aromatic structure can be, and often is, Rc.


“Fused ring aromatic” or polynuclear or polycyclic aromatic moieties are, of course well known. These moieties are characterized by the presence of at least two aromatic rings sharing a pair of carbon atoms. The best known examples of fused ring aromatic moieties are probably naphthalene, carbazole, anthracene, and phenanthrene. Their moieties, i.e., naphthyl, anthracyl, carbazole, and phenanthryl, are examples of preferred moieties of the high RI monomer. Further examples of such fused-ring aromatic molecules and hence their moieties include:




embedded image


The above list is, of course, non-limiting. Further, the unsaturation moiety can be coupled to any one of the outer ring carbons of the above structures as would be readily apparent to one skilled in this art.


In a preferred practice, the high RI monomer comprises multimers including: a carbazole and or naphthyl moiety, the carbazole/naphthyl moiety monomer being present in the composition at a concentration of at least 15% and preferably up to about 25-45%.


The composition further includes a second monomer with a hydrophobic homopolymer, the hydrophobicity being defined as the homopolymer having a surface tension of about 50 dyn/cm or less, the second monomer being present in the copolymer, in an amount of at least about 20 weight percent, preferably about 50-60 weight percent.


The composition further includes at least about 10 weight percent of a hydrophilic monomer, preferably about 20-30 weight percent. The composition then includes a crosslinking monomer, the crosslinking monomer being present at a concentration in the range up to 10 weight percent, preferably of about 1 weight percent to about 8 weight percent.


Suitable hydrophilic monomers (i.e., monomers whose homopolymers are hydrophilic in accordance with this invention) include but are not limited to 2-hydroxy-ethylacrylate, 2-hydroxyethylmethacrylate, acrylamide, N-ornithine acrylamide, N-(2-hydroxypropyl)acrylamide, polyethyleneglycol acrylates, polyethyleneglycol methacrylates, N-vinyl pyrolidone, N-phenylacrylamide, dimethylaminopropyl methacrylamide, acrylic acid, benzylmethacrylamide, 4-hydroxybutylmethacrylate, glycerol mono methacrylate, glycerol mono acrylate, 2-sulfoethylmethacrylate, phenoxyethyl acrylate, phenoxy ethyl methacrylate, 2-(2-ethoxyethoxy)ethyl acrylate, 2-(2-ethoxyethoxy)ethyl methacrylate, furfuryl acrylate, furfaryl methacrylate, and methylthioethylacrylamide.


Suitable hydrophobic monomers (i.e., monomers whose homopolymers are hydrophobic in accordance with this invention) include, but are not limited to, Lauryl methacrylate, lauryl acrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, n-decyl acrylate, n-decyl methacrylate, hexyl acrylate, hexyl metcarylate, stearyl acrylate, stearyl methacrylate, isodecyl acrylate, isodecyl methacrylate, isobornyl acrylate, isobornyl methacrylate, vinyl laurate, vinyl stearate, 1-hexadecyl acrylate, 1-hexadecyl methacrylate, n-myristyl acrylate, n-myristyl methacryalte, n-dodecyl methacrylamide, butyl acrylate, n-butyl methacrylate, isooctyl acrylate, isotridecyl acrylate, isooctyl methacrylate, and isotridecyl methacrylate.


Suitable crosslinkers include, for example, but are not limited to, ethylene glycol dimethacrylate (EGDMDA), diethylene glycol dimethacrylate, and triethylene glycol dimethacrylate and poly (ethylene glycol) dimethacrylate wherein ethylene glycol dimethacrylate is preferred. Suitable initiators include, for example, but are not limited to, azobis(isobutyronitrile), 2,2′-azobis(2,4-dimethylvaleronitdle), 2,2′-azobis (methylbutyronitrile), 1,1′-azobis(cyanocyclohexane), di-t-butyl peroxide, dicumyl peroxide, t-butylcumyl peroxide, 2,5-dimethyl-2,5-bis(2-ethylhexanoyl peroxy)hexane, t-butyl peroxyneodecanote, t-butyl peroxy 2-ethylhexanoate, di(4-t-butyl cyclohexyl) peroxydicarbonate, t-butyl peroxypivalate, decanoyl peroxide, lauroyl peroxide, benzoyl peroxide, 2,4-pentanedione peroxide, di(n-propyl) peroxydicarbonate, t-amyl peroxyneodecanoate and t-butyl peroxyacetate wherein 2,2′-azobis(isobutyronitrile) is preferred.


Suitable ultraviolet light absorbers include for example but are not limited to beta-(4-benzotriazoyl-3-hydroxyphenoxy) ethyl acrylate, 4-(2-acryloxyethoxy)-2-hydroxybenzophenone, 4-methacryloxy-2-hydroxybenzo-phenone, 2-(2′-methacryloxy-5′-methylphenyl) benzotriazole, 2-(2′-hydroxy-5′-methacryoxyethylphenyl)-2H-benzo-triazole, 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″-methacryloyloxypropyl)phenyl]-5-chloro-benzotriazole, 2-(3′-tert-Butyl-5′-[3″-dimethylvinyisilylpropoxy)-2′-hydro-xyphenyl]-5-methoxybenzotriazole, 2-(3′-Allyl-2′-hydroxy-5′-methylphenyl) benzo-triazole, 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″ methacryloyloxypropoxy) phenyl]-5-methoxybenzotriazole, and 2-[3′-tert-Butyl-2′-hydroxy-5′-(3″-methacryloyloxypropoxy) phenyl]-5-chlorobenzo-triazole wherein beta-(4-benzotriazoyl-3-hydroxyphen-oxy)ethyl acrylate is the preferred ultraviolet light absorber.


A UV absorber optionally may be added to the copolymer compositions. A novel, preferred, UV/blue light absorber, i.e., vinyl anthracene, may be added to the copolymer compositions. Conventional U.V. absorbers such as a vinyl benzophenone or a vinyl benzotriazole also may be used.


A monomeric dye capable of copolymerizing with the hydrophobic and the hydrophilic monomers optionally may be added to the copolymer to attenuate specific wavelengths of light. Such dyes include but are not limited to those containing vinyl groups and are capable of absorbing violet, blue, red, and green light in the range of 400-700 nm.


Examples of such monomeric dyes include but are not limited to:

  • Disperse Red 13 acrylate,
  • Disperse Orange 3 acrylamide
  • Disperse Orange 3 methacrylamide
  • Disperse Red 1 methacrylate
  • Disperse Red 1 acrylate
  • Disperse Red 13 methacrylate
  • Disperse yellow 7 acrylate
  • Disperse yellow 7 methacrylate
  • Ethyl trans-α-cyano-3-indoleacrylate
  • [(S)-(−)-1-(4-Nitrophenyl)-2-pyrrolidinemethyl]acrylate


GENERAL PREPARATION STEPS FOR POLYMERS OF EXAMPLES 1-15

The comonomers listed below were mixed in a glass flask using a magnetic stir bar for at least 30 minutes, at room temperature followed by sonication for the times indicated, and then stirring again for another 30 minutes. The combination of sonication and hydrophilic/hydrophobic repulsion forces allows the formation of nanoclusters. The size of the nanoclusters is theoretically controlled by the amount of energy provided during these steps. It was found that sonicating for about 30 minutes at a power setting of 100% on a Branson 5510 sonicator provides optically clear materials with adequate optical and physical properties. Sonicating time may vary between 1 minutes to 60 minutes depending on the formulation used. It has also been found that an optional second sonication step of at least about 10 minutes is sometimes needed to produce materials of the desired optical characteristics.


The resulting copolymers are rigid enough to be machined at around room temperature. A unique and surprising aspect of the above materials is that the refractive index of the copolymers is so high that ophthalmic lenses can be made thin enough to be folded without further processing or hydration.


Examples 1-15



















Cocentra-

%




Monomer
tion
RI
EWC
Processing conditions





















Ex. 1
VC
30
1.5690
1.5
20 minutes sonication



LM
37


twice



HEMA
30



EGDM
3


Ex. 2
VC
30
1.5687
1.7
25 minutes sonication



LM
37


twice



HEA
30



EGDM
3


Ex. 3
VC
30
1.5634
1.8
15 minutes sonication



EHA
37



HEMA
30



EGDM
3


Ex. 4
VC
30
1.5623
1.7
15 minutes sonication



EHA
37



HEA
30



EGDM
3


Ex. 5
VN
30
1.5541
1.7
10 minutes sonication



EHA
37



HEMA
30



EGDM
3


Ex. 6
VC
30
1.5512
1.6
10 minutes sonication



EHA
37



HEA
30



EGDM
3


Ex. 7
VC
25
1.5476
1.4
15 minutes sonication



EHA
52



HEMA
20



EGDM
3


Ex. 8
VC
25
1.5442
1.7
15 minutes sonication



EHA
52



HEA
20



EGDM
3


Ex. 9
VC
35
1.5623
1.7
10 minutes sonication



EHA
47



HEMA
15



EGDM
3


Ex. 10
VC
35
1.5601
1.1
15 minutes sonication



EHA
47


twice



HEMA
10



EGDM
3









Preferred Formulations












Ex. 11
VC
30
1.5590
1.2
30 minutes sonication



EHA
42



HEMA
25



EGDM
3


Ex. 12
VC
27.5
1.5510
1.0
30 minutes sonication



LM
44.0


twice



HEA
25.5



EGDM
3


Ex. 13
VC
27.0
1.5500
1.0
30 minutes sonication



LM
42.0


twice



HEA
24.0



EGDM
0.25



VA
0.45


Ex. 14
VC
27.0
1.5511
1.0
30 minutes sonication



LM
44.5


twice



HEA
25.0



EGDM
2.5



DR1
0.02


Ex. 15
VC
27.0
1.5505
1.0
30 minutes sonication



LM
44.5


twice



HEA
25.0



EGDM
2.5



DR1
0.01





2.5% by weight of VA and 0.3% by weight of MEB was used in all copolymer compositions.


VC: vinyl carbazole


VN: 2-vinyl naphthalene


EHA: 2-ethylhexylacrylate


LM: Lauryl methacrylate


HEMA; Hyroxyethylmethacrylate


HEA: Hydroxyethylacrylate


EGDM: ethylene glycol dimethacrylate


VA: vinyl anthracene


MEB: 2-(2′-Methacryloxy-5′methylphenyl)benzotriazole


DR 1: Disperse Red 1 Methacrylate





Claims
  • 1. A copolymer comprising: a) a high refractive index monomer comprising;
  • 2. A copolymer of claim 1 wherein the high refractive index monomer comprises an ethylenically unsaturated moiety and a fused ring aromatic moiety.
  • 3. A copolymer of claim 2 wherein the ethylenically unsaturated moiety comprises:
  • 4. A copolymer in accordance with claim 1, wherein the high refractive index monomer is selected from the group consisting of vinyl carbazole, vinyl naphthalene, and vinyl anthracene.
  • 5. A copolymer according to claim 1 which comprises: a) at least about 15% by weight high refractive index monomer;b) at least about 20 weight percent hydrophobic monomer;c) at least about 10 weight percent hydrophilic monomer.
  • 6. A copolymer according to claim 5 wherein the high refractive index monomer is selected from the group consisting of vinyl naphthalene, vinyl carbazole, and vinyl anthracene.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 11/005,820, filed Dec. 7, 2004, now U.S. Pat. No. 7,446,157 which is incorporated herein by reference. Concurrently filed herewith is a second divisional application, (entitled Nanohybrid Polymers for Ophthalmic Applications), which is also a divisional of parent patent application Ser. No. 11/005,820, filed Dec. 7, 2004. The disclosure of that second divisional application is also incorporated by reference herein.

US Referenced Citations (85)
Number Name Date Kind
2461460 Winnek Feb 1949 A
2989529 Schuler Jun 1961 A
4304895 Loshaek Dec 1981 A
4312725 Loshaek et al. Jan 1982 A
4390676 Loshaek Jun 1983 A
4528311 Beard Jul 1985 A
4595548 St. Clair et al. Jun 1986 A
4603061 St. Clair et al. Jul 1986 A
4611892 Kawashima Sep 1986 A
4636212 Posin Jan 1987 A
4665123 Goldenberg May 1987 A
4719248 Bambury Jan 1988 A
4731079 Stoy Mar 1988 A
4834750 Gupta May 1989 A
4851521 della Valle et al. Jul 1989 A
4863539 Lee Sep 1989 A
4872877 Tiffany Oct 1989 A
5080688 Cohen Jan 1992 A
5093408 Jung Mar 1992 A
5098445 Hung Mar 1992 A
5132384 Matsuda Jul 1992 A
5194544 Goldberg Mar 1993 A
5217491 Vanderbilt Jun 1993 A
5290892 Namdaran Mar 1994 A
5326506 Vanderbilt Jul 1994 A
5331073 Weinschenk Jul 1994 A
5338826 St. Clair et al. Aug 1994 A
5359021 Weinschenk Oct 1994 A
5374663 Daicho Dec 1994 A
5403901 Namdaran Apr 1995 A
5428102 St. Clair et al. Jun 1995 A
5433746 Namdaran Jul 1995 A
5470932 Jinkderson Nov 1995 A
5480950 Wang Jan 1996 A
5496368 Wiese Mar 1996 A
5528322 Jinkerson Jun 1996 A
5543504 Jinkerson Aug 1996 A
5556931 Imura Sep 1996 A
5603774 LeBoeuf Feb 1997 A
5608471 Miller Mar 1997 A
5639850 Bryant Jun 1997 A
5654350 Nunez Aug 1997 A
5662707 Jinkerson Sep 1997 A
5674960 Namdaran Oct 1997 A
5693095 Freeman Dec 1997 A
5728157 Prescott Mar 1998 A
5741883 Bryant Apr 1998 A
5776191 Mazzocco Jul 1998 A
5789463 Odagiri Aug 1998 A
5814680 Imafuku Sep 1998 A
5821306 Hodd Oct 1998 A
5842971 Yoon Dec 1998 A
5849841 Muhlebach Dec 1998 A
5855825 Ito Jan 1999 A
5856370 Chmelir Jan 1999 A
5861031 Namdaran Jan 1999 A
5891931 LeBoeuf Apr 1999 A
5922550 Everhart Jul 1999 A
5922821 LeBoeuf Jul 1999 A
5945498 Hopken Aug 1999 A
6030078 Ocampo Feb 2000 A
6048951 Wunsch et al. Apr 2000 A
6149692 Lally Nov 2000 A
6150479 Klemarczyk Nov 2000 A
6201061 Amagai Mar 2001 B1
6201089 Carter Mar 2001 B1
6218463 Molock Apr 2001 B1
6265465 Benz Jul 2001 B1
6271281 Liao Aug 2001 B1
6281319 Mentak Aug 2001 B1
6329485 Vanderbilt Dec 2001 B1
6342570 Bothe et al. Jan 2002 B1
6673888 Kosaka Jan 2004 B2
20010049400 Alli Dec 2001 A1
20020037984 Vanderbilt Mar 2002 A1
20020042483 Vanderbilt Apr 2002 A1
20020042484 Vanderbilt Apr 2002 A1
20020049290 Vanderbilt Apr 2002 A1
20020064513 Maitra May 2002 A1
20020156047 Zhao Oct 2002 A1
20030099694 Ceve May 2003 A1
20030170893 Unger Sep 2003 A1
20040063200 Chaikof et al. Apr 2004 A1
20040147501 Dolmans Jul 2004 A1
20040156880 Ravi Aug 2004 A1
Foreign Referenced Citations (24)
Number Date Country
0485197 Oct 1996 EP
0826158 Sep 1999 EP
0820601 Dec 1999 EP
1 431 350 Jun 2004 EP
2171106 Aug 1986 GB
2381482 May 2003 GB
WO 9325593 Dec 1993 WO
WO 9505164 Feb 1995 WO
WO 9522991 Aug 1995 WO
WO 9618498 Jun 1996 WO
WO 9631791 Oct 1996 WO
WO 9636890 Nov 1996 WO
WO 9640303 Dec 1996 WO
WO 9724382 Jul 1997 WO
WO 9853920 Dec 1998 WO
WO 9901034 Jan 1999 WO
WO 0014591 Mar 2000 WO
WO 0034804 Jun 2000 WO
WO 0118078 Mar 2001 WO
WO 0118079 Mar 2001 WO
WO 0125301 Apr 2001 WO
WO 0209647 Feb 2002 WO
WO 03000777 Jan 2003 WO
WO 2004044012 May 2004 WO
Related Publications (1)
Number Date Country
20080064840 A1 Mar 2008 US
Divisions (1)
Number Date Country
Parent 11005820 Dec 2004 US
Child 11942527 US